HCPCS Level II code J0517 designates a 1 mg unit of benralizumab, a monoclonal antibody administered by injection for management of certain eosinophilic respiratory conditions. As a drug-specific HCPCS code, J0517 is used on medical claims to report the billed quantity of benralizumab supplied and is central to pharmacy-oncology and specialty drug reimbursement workflows nationwide. The code matters nationally because biologic therapies represent high-cost, high-impact services with complex coverage and utilization controls across payers.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of clinical context for benralizumab use, the service setting and billing implications for injectable biologics, and what to expect in payer coverage policies and billing practice. The publication summarizes common billing considerations, typical sites of service and service line implications, and provides benchmarks and policy-relevant issues where available. Data not available in the input will be noted explicitly where necessary.